ClinicalTrials.gg
CompletedNCT03260790Updated Nov 5, 2021Results posted

Pneumococcal Vaccines in Patients With Asthma

A Phase 4 interventional study of PCV13 and PPSV23 in Asthma, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 19 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-11-05.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,695 studies in Asthma with a site in United States — 134 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
1,178th of 1,353
17 · median 100
Started
2017
with 82 others
Phase 4
158 of 1,695
11 open now
Registered
1,174th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 1,178th largest by enrollment of the 1,353 interventional ones that give a count, is one of 83 that started in 2017, is one of 158 in phase 4, and was the 1,174th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

134 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

Read the detailed description

Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone (Active comparator). At the Week 0 time point, the patients will receive either PCV13 (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype titers as well as a blood draw at week 16 and week 24.

03

Conditions studied

  • Asthma

Keywords

  • Vaccine
  • Pneumococcal
  • Pneumonia
04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma

Exclusion criteria

Exclusion Criteria:

  • Research exemption requested
  • History of PCV-13 vaccination
  • History of cochlear implant
  • Cerebrospinal Fluid (CSF) leak
  • Congestive Heart Failure (CHF)
  • Diabetes Mellitus (DM)
  • Chronic Kidney Disease (CKD)
  • (HIV)
  • Common Variable Immune Deficiency (CVID)
  • Patients who have received the PPSV23 vaccine in the last 5 years
  • Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    PCV13 and PPSV23

    Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23

    Biological: PCV13 · Biological: PPSV23

  • Active comparator
    PPSV23

    Participants randomized to receive PPSV23 alone

    Biological: PPSV23

Interventions

06

What researchers measure

Primary outcomes

  1. Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16

    5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.

    Time frame: Baseline, week 0, week 8, week 16

  2. Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16

    5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.

    Time frame: Baseline, week 0, week 8, week 16

  3. Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16

    5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 \& PPSV23. Measured as mcg/mL.

    Time frame: Baseline, week 0, week 8, week 16

  4. Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.

    5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.

    Time frame: Baseline, week 0, week 8, week 16

07

Results

Posted Nov 5, 2021

Participant flow

Participant flow — Overall Study
MilestonePCV13 and PPSV23PPSV23
Started89
Completed89
Not completed00

Outcome measures

PrimaryTotal Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16

5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.

Time frame:
Baseline, week 0, week 8, week 16
Reported as:
Median · mcg/dL
Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16
mcg/dLPCV13 and PPSV23PPSV23
baseline109.8 (74.3 to 141.8)53.9 (34.8 to 185.3)
week 0142.3 (111.7 to 194.6)53.9 (34.8 to 185.3)
week 8211.7 (184.6 to 271.0)243.3 (173.4 to 271.0)
week 16212.0 (171.1 to 257.7)224.8 (196.6 to 271.0)
PrimarySum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16

5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.

Time frame:
Baseline, week 0, week 8, week 16
Reported as:
Median · mcg/mL.
Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16
mcg/mL.PCV13 and PPSV23PPSV23
baseline228.0 (174.2 to 362.3)206.8 (130.1 to 323.8)
week 0506.3 (349.6 to 670.9)206.8 (130.1 to 323.8)
week 8502.9 (369.9 to 790.5)449.4 (338.7 to 583.4)
week 16534.8 (325.4 to 688.4)485.7 (321.2 to 588.6)
PrimarySum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16

5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 \& PPSV23. Measured as mcg/mL.

Time frame:
Baseline, week 0, week 8, week 16
Reported as:
Median · mcg/mL
Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16
mcg/mLPCV13 and PPSV23PPSV23
baseline142.4 (110.7 to 246.8)107.4 (92.9 to 161.8)
week 0418.9 (303.2 to 525.1)107.4 (92.9 to 161.8)
week 8362.8 (258.9 to 498.6)229.4 (162.6 to 302.2)
week 16343.7 (221.5 to 447.1)230.5 (149.5 to 302.1)
PrimarySum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.

5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.

Time frame:
Baseline, week 0, week 8, week 16
Reported as:
Median · mcg/mL
Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.
mcg/mLPCV13 and PPSV23PPSV23
baseline89.2 (64.1 to 120.9)74.7 (41.0 to 160.2)
week 082.4 (56.2 to 152.4)74.7 (41.0 to 160.2)
week 8174.2 (92.3 to 283.4)220.0 (164.7 to 246.8)
week 16179.1 (96.9 to 277.0)184.1 (171.0 to 255.2)

Adverse events

Collected over Adverse Events were collected from baseline to end of study, approximately 16 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCV13 and PPSV230/8 (0%)0/8 (0%)0/8 (0%)
PPSV230/9 (0%)0/9 (0%)0/9 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PCV13 and PPSV23PPSV23Total
<=18 years000
Between 18 and 65 years8816
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)PCV13 and PPSV23PPSV23Total
Female7815
Male112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PCV13 and PPSV23PPSV23Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8816
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)PCV13 and PPSV23PPSV23Total
United States8917
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2020, 38 months.

Results were first posted in Nov 2021, 10 months after primary completion.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 38 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2017
First posted
Aug 24, 2017
StartActual
Oct 1, 2017
Primary completionActual
Dec 21, 2020
CompletionActual
Dec 25, 2020
Results first posted
Nov 5, 2021
Last update
Nov 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03260790
Lead sponsor
Mayo Clinic
Responsible party
Avni Joshi (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 24, 2017
Start date
Oct 1, 2017
Primary completion
Dec 21, 2020
Completion
Dec 25, 2020
Results posted
Nov 5, 2021
Last update
Nov 5, 2021

Study contacts

Avni Y Joshi
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion